Orelabrutinib is a Class 1 innovative drug independently developed by Nuocheng Jianhua, a local biopharmaceutical enterprise in China. As a highly selective Bruton's tyrosine kinase (BTK) inhibitor, it is mainly indicated for the treatment of hematological malignancies such as lymphoma. Approved for marketing by the National Medical Products Administration (NMPA) of China in December 2020, it stands as a significant achievement in China's innovative drug research and development.
Detailed Description
1. R&D and Manufacturing Background
Founded in 2015 and headquartered in Beijing, Nuocheng Jianhua is a biopharmaceutical company dedicated to the development of innovative drugs for oncology and autoimmune diseases. Its R&D pipeline is entirely built on independent core technologies. Both the clinical trials and marketing application of orelabrutinib were completed in China, making it a typical representative of domestically-developed innovative drugs.
2. Approved Indications
Orelabrutinib is currently approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It exerts its therapeutic effect by inhibiting Bruton's tyrosine kinase (BTK) to block the B-cell receptor signaling pathway, thereby suppressing tumor cell proliferation.
3. Drug Characteristics
As a domestically-developed third-generation BTK inhibitor, orelabrutinib features high selectivity and low off-target effects, which can reduce the bleeding or immune-related adverse reactions that may be caused by traditional BTK inhibitors. Clinical research data have shown that it yields a significant objective response rate (ORR) in patients with specific types of lymphoma and exhibits good tolerability.
4. Precautions for Use
Orelabrutinib is a prescription-only medicine and must be used strictly in accordance with the doctor's instructions. Dosage adjustment or discontinuation without medical advice is prohibited. Common adverse reactions include thrombocytopenia, diarrhea, and fatigue. During the medication period, regular monitoring of blood routine, liver function, and renal function is required. Contraindicated populations include patients with moderate to severe hepatic or renal insufficiency, as well as pregnant and lactating women. Specific eligibility should be determined based on clinical evaluation.
5. Drug Accessibility
This drug was included in the National Reimbursement Drug List of China in 2021, which has significantly alleviated the economic burden on patients. However, it should still be purchased through formal medical institution channels to ensure medication safety.
If you have relevant disease symptoms or medication needs, it is recommended to consult a hematologist or oncologist in a timely manner, and the treatment plan will be formulated based on professional medical evaluation.
